Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999902 · ClinicalTrials.gov registry record · Phase 2
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
A Phase 2 study of Focal Seizure, sponsored by Praxis Precision Medicines.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT06999902: Recruiting Phase 2 study of Focal Seizure, sponsored by Praxis Precision Medicines.
NCT06999902 is a Phase 2 study of Focal Seizure that is actively recruiting participants, run by Praxis Precision Medicines. The registered enrollment target is 230 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999902, a Phase 2 study of Focal Seizure, is actively recruiting participants, sponsored by Praxis Precision Medicines.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
Primary Outcome
Median percent change in monthly (28 days) focal seizure frequency from the Screening/Observation Period to the Treatment Period for PRAX-628 compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Study Locations (20)
Texas
- Praxis Research Site - El Paso
- Praxis Research Site - Frisco
- Praxis Research Site - Round Rock
- Praxis Research Site - Seabrook
Other
- Praxis Research Site - Barcelona
- Praxis Research Site - Barcelona
- Praxis Research Site - Barcelona
- Praxis Research Site - Granda
Florida
- Praxis Research Site - DeLand
- Praxis Research Site - Miami Lakes
Missouri
- Praxis Research Site - Chesterfield
- Praxis Research Site - Ozark
Arizona
- Praxis Research Site - Phoenix
Illinois
- Praxis Research Site - Chicago
Louisiana
- Praxis Research Site - Lafayette
Maryland
- Praxis Research Site - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
What NCT06999902 shows while recruiting
NCT06999902 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher).
The record links to 1 condition, with Focal Seizure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06999902 names 20 study sites across 12 states, led by Texas, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT06999902 about?
NCT06999902 is a clinical study titled "Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)". A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
What is the current status of trial NCT06999902?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2024-12-11. Estimated completion is 2025-12-08.
What conditions does trial NCT06999902 study?
This clinical trial studies the following conditions: Focal Seizure.
What interventions are being tested in trial NCT06999902?
The interventions under investigation include: Placebo (DRUG), 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks (DRUG).
Who is sponsoring clinical trial NCT06999902?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999902 being conducted?
This trial has 20 study locations across Arizona, Florida, Illinois, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Seizure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06999902's enrollment target sits among peer trials
230 257th of 2000 higher than 1,738 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI